Reported Earlier, Telix Reports Q3 2026 Group Revenue Of $245M, Up 19% YoY, With Precision Medicine Revenue Up 30% YoY To $201M On Gozellix And Illuccix Demand

뉴스 본문을 불러오고 있어요.

Reported Earlier, Telix Reports Q3 2026 Group Revenue Of $245M, Up 19% YoY, With Precision Medicine Revenue Up 30% YoY To $201M On Gozellix And Illuccix Demand | 웨이프 WAPE

Reported Earlier, Telix Reports Q3 2026 Group Revenue Of $245M, Up 19% YoY, With Precision Medicine Revenue Up 30% YoY To $201M On Gozellix And Illuccix Demand

기사 요약

관련 종목

댓글 —